Search

Your search keyword '"Tatsuki Yoshida"' showing total 10 results
Start Over Author "Tatsuki Yoshida"
10 results on '"Tatsuki Yoshida"'

1. Disproportionate cancer worries in ultra‐short‐segment Barrett's esophagus in Japan

Author

Sho Fukuda, Kenta Watanabe, So Takahashi, Tatsuki Yoshida, Shusei Fujimori, Taiga Komatsu, Yosuke Shimodaira, Tamotsu Matsuhashi, and Katsunori Iijima

Subjects
Barrett's esophagus, cancer perception, cancer risk, cancer worry, questionnaire survey, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Objectives Although Barrett's esophagus (BE), especially ultra‐short‐segment BE (USSBE), is very frequently diagnosed in Japan, how subjects feel about receiving a diagnosis of BE is unclear. We therefore prospectively investigated cancer worry in subjects who received a BE diagnosis. Methods Self‐administered questionnaires were sent to subjects who were diagnosed with BE at three health checkup institutes in Akita Prefecture, Japan. The cancer worry scale (CWS) was used to quantitatively assess the fear of developing cancer. The BE subjects were classified into USSBE

Published
2024
Full Text
View/download PDF

2. A Final Report on the Real Impact of the COVID-19 Pandemic on the Diagnosis of Gastrointestinal Cancer in Akita Prefecture, Japan in 2022.

Author

Katsunori Iijima, Kenta Watanabe, Yosuke Shimodaira, Shigeto Koizumi, Sho Fukuda, Tatsuki Yoshida, Ryo Ookubo, Tamotsu Matsuhashi, Mario Jin, Masahito Miura, and Hiroyuki Shibata

Abstract

The long-term impact of the coronavirus disease 2019 (COVID-19) pandemic on the disruption of gastrointestinal cancer diagnoses remains unclear. This study investigated the actual impact on esophagogastric cancer (EGC) and colorectal cancer (CRC) diagnoses up to the third year of the pandemic in Akita Prefecture, Japan, using population-based registry data. We collected data on the annual number of EGC and CRC diagnoses using a database from the collaborative Akita Prefecture hospital-based registration. The net number of cancers diagnosed in the first three years of the pandemic (2020-2022) were compared with those diagnosed in the three years before the pandemic (2017-2019). Changes in the proportion of cancer stage and initial treatment for diagnosed EGC and CRC after the pandemic were then compared. The total number of EGCs was 9.3% lower in the first three years of the pandemic than in the three years before, probably due to its long-term declining trend. The total number of CRCs in the first three years of the pandemic exceeded that in the three years before, suggesting successful recovery of the diagnostic procedure. The proportion of cancer stages and initial treatment for EGCs and CRCs remained largely unchanged after the onset of the pandemic. Based on the population-based registry data from the first three years of the pandemic, the disruption of gastrointestinal cancer diagnoses caused by the pandemic is settling down without any substantial disease progression, even in Akita Prefecture, the area with the highest incidence of cancer in all of Japan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease

Author

Tatsuki, Yoshida, Yosuke, Shimodaira, Sho, Fukuda, Noboru, Watanabe, Shigeto, Koizumi, Tamotsu, Matsuhashi, Kengo, Onochi, and Katsunori, Iijima

Subjects
Inflammation, Constriction, Pathologic, General Medicine, Inflammatory Bowel Diseases, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, C-Reactive Protein, Crohn Disease, Leucine, Humans, Colitis, Ulcerative, Biomarkers, Glycoproteins, Retrospective Studies
Abstract

Leucine-rich alpha-2 glycoprotein (LRG) is a novel biomarker for monitoring disease activity in inflammatory bowel disease (IBD). The aim of this study was to evaluate its utility in monitoring disease activity. In this retrospective study based on case records between August 2020 and July 2021 at our two centers, we examined the correlation between serum levels of LRG and C-reactive protein (CRP) with disease activity in IBD patients. Background factors related to serum LRG levels were also analyzed. Overall, 47 Crohn's disease (CD) and 123 ulcerative colitis (UC) patients were evaluated. In patients with CD, LRG and CRP levels correlated with Harvey-Bradshaw Index (HBI) and Simple Endoscopic Score for CD (SES-CD) (LRG and HBI, r = 0.397; LRG and SES-CD, r = 0.637; CRP and HBI, r = 0.253; CRP and SES-CD, r = 0.332). In patients with UC, LRG and CRP significantly correlated with the partial Mayo score (PMS) and Mayo endoscopic subscore (MES) (LRG and PMS, r = 0.3; CRP and PMS, r = 0.282; LRG and MES, r = 0.424; CRP and MES, r = 0.459). In CD patients with normal CRP, serum LRG level was significantly higher in those with mucosal inflammation than in those with mucosal healing (16.4 vs. 10.7 μg/ mL). Stenosis was associated with serum LRG levels in CD group using multiple regression analysis. Therefore, LRG is a useful biomarker for monitoring disease activity and mucosal inflammation, and indicates the status of intestinal stenosis in IBD patients.

Published
2022

7. Low risk of esophageal adenocarcinoma among patients with ultrashort‐segment Barrett's esophagus in Japan

Author

Sho Fukuda, Katsunori Iijima, Shusei Fujimori, Taiga Komatsu, Kenta Watanabe, Tatsuki Yoshida, Yosuke Shimodaira, So Takahashi, Tamotsu Matsuhashi, Kenji Shirane, and Yohei Horikawa

Subjects
medicine.medical_specialty, Esophageal Neoplasms, Population, Esophageal adenocarcinoma, Adenocarcinoma, Gastroenterology, Barrett Esophagus, Japan, Stomach Neoplasms, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Esophagus, education, Retrospective Studies, education.field_of_study, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Cancer, medicine.disease, digestive system diseases, Endoscopy, medicine.anatomical_structure, Barrett's esophagus, Atrophy, business, Follow-Up Studies, Endoscopic image
Abstract

OBJECTS Ultrashort-segment Barrett's esophagus (USSBE; length of

Published
2021

8. Arylation of aryllithiums with S-arylphenothiazinium ions for biaryl synthesis

Author

Naokazu Kano, Masahiro Yamanaka, Tatsuki Yoshida, Tatsuya Morofuji, and Ryosuke Tsutsumi

Subjects
Chemistry, Aryl, Metals and Alloys, General Chemistry, Combinatorial chemistry, Catalysis, Surfaces, Coatings and Films, Electronic, Optical and Magnetic Materials, Ion, chemistry.chemical_compound, Nucleophile, Ligand coupling, Materials Chemistry, Ceramics and Composites
Abstract

Aryllithiums are one of the most common and important aryl nucleophiles; nevertheless, methods for arylation of aryllithums to produce biaryls have been limited. Herein, we report arylation of aryllithiums with S-arylphenothiazinium ions through selective ligand coupling of intermediary sulfuranes. Various unsymmetrical biaryls could be obtained without transition-metal catalysis.

Published
2020

9. Arylation of aryllithiums with

Author

Tatsuya, Morofuji, Tatsuki, Yoshida, Ryosuke, Tsutsumi, Masahiro, Yamanaka, and Naokazu, Kano

Abstract

Aryllithiums are one of the most common and important aryl nucleophiles; nevertheless, methods for arylation of aryllithums to produce biaryls have been limited. Herein, we report arylation of aryllithiums with S-arylphenothiazinium ions through selective ligand coupling of intermediary sulfuranes. Various unsymmetrical biaryls could be obtained without transition-metal catalysis.

Published
2020

10. Successful treatment of hepatocellular carcinoma with lung metastasis using hepatic and bronchial artery infusion chemotherapy

Author

Kentaro Kamada, Ryo Kanata, Itsuki Hasegawa, Manabu Hashimoto, Hirohide Ohnishi, Yuko Sugimoto, Takashi Goto, Kouichi Miura, Toshitaka Sakai, Akashi Fujita, Tatsuki Yoshida, Junichi Fujiwara, Kenichi Takahashi, Takahiro Dohmen, Wataru Sato, Mitsuaki Ishioka, Shinichiro Minami, Shigetoshi Ohshima, Tomomi Shibuya, and Mitsuru Chiba

Subjects
Sorafenib, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Lung Neoplasms, medicine.medical_treatment, Antineoplastic Agents, Bronchial Arteries, Gastroenterology, Hepatic Artery, Internal medicine, medicine.artery, Internal Medicine, medicine, Carcinoma, Humans, Infusions, Intra-Arterial, Cisplatin, Chemotherapy, Lung, business.industry, Liver Neoplasms, General Medicine, respiratory system, Middle Aged, medicine.disease, Thrombosis, digestive system diseases, respiratory tract diseases, medicine.anatomical_structure, Hepatocellular carcinoma, Radiology, business, Bronchial artery, medicine.drug
Abstract

We herein report a case of hepatocellular carcinoma (HCC) with lung metastasis that was successfully treated with transcatheter arterial infusion chemotherapy via the hepatic and bronchial arteries. A 64-year-old man diagnosed with HCC in 2003 was treated with locoregional therapy followed by sorafenib for recurrent HCC. Tumor thrombosis and lung metastasis were noted in April 2012. We administered IA-call(®), a fine-powder formulation of cisplatin, via the hepatic and bronchial arteries. This therapy resulted in the disappearance of the lung metastases and a partial response to tumor thrombosis. The patient remained alive for 23 months after developing lung metastasis.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results